OncoSec Medical Inc (ONCSQ)

[hschlauch]

Adoptive transfer of T cells is so darn expensive because it requires sampling, engineering, and expansion of the immune cells. This obviously works for blood cancers.

Another alternative for solid tumors, probably a MUCH cheaper route, is to identify the neoantigens on the tumors, select from a library of encoded antigens that are already p2a-linked with encoded immune stimulatory agents (e.g. IL-12) on plasmids, electroporate the plasmid in the tumor, and let the body manufacture the T-cells. This would have to be combined with checkpoint inhibitors.

Even better in my opinion, direct the body to stimulate an in situ vaccination. Find a way to expose the tumor's unique antigens in the presence of professional antigen presenting cells. Let the body do the hard work - just find the correct combination of encoded proteins that will stimulate the immunity after electroporation. Again, checkpoint inhibitors will still have to be used.